99 related articles for article (PubMed ID: 30352674)
1. NFκB and MHC-1 Interplay in Neuroblastoma and Immunotherapy.
Spel L; Schiepers A; Boes M
Trends Cancer; 2018 Nov; 4(11):715-717. PubMed ID: 30352674
[TBL] [Abstract][Full Text] [Related]
2. Nedd4-Binding Protein 1 and TNFAIP3-Interacting Protein 1 Control MHC-1 Display in Neuroblastoma.
Spel L; Nieuwenhuis J; Haarsma R; Stickel E; Bleijerveld OB; Altelaar M; Boelens JJ; Brummelkamp TR; Nierkens S; Boes M
Cancer Res; 2018 Dec; 78(23):6621-6631. PubMed ID: 30213788
[TBL] [Abstract][Full Text] [Related]
3. Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes.
Vertuani S; De Geer A; Levitsky V; Kogner P; Kiessling R; Levitskaya J
Cancer Res; 2003 Nov; 63(22):8006-13. PubMed ID: 14633733
[TBL] [Abstract][Full Text] [Related]
4. Reprogramming of the MHC-I and its regulation by NFκB in human-induced pluripotent stem cells.
Pick M; Ronen D; Yanuka O; Benvenisty N
Stem Cells; 2012 Dec; 30(12):2700-8. PubMed ID: 22987393
[TBL] [Abstract][Full Text] [Related]
5. Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.
Rickard S; Ono SJ
Exp Mol Pathol; 2008 Dec; 85(3):147-54. PubMed ID: 18952077
[TBL] [Abstract][Full Text] [Related]
6. NF-kappaB, and not MYCN, regulates MHC class I and endoplasmic reticulum aminopeptidases in human neuroblastoma cells.
Forloni M; Albini S; Limongi MZ; Cifaldi L; Boldrini R; Nicotra MR; Giannini G; Natali PG; Giacomini P; Fruci D
Cancer Res; 2010 Feb; 70(3):916-24. PubMed ID: 20103633
[TBL] [Abstract][Full Text] [Related]
7. IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.
Kloess S; Huenecke S; Piechulek D; Esser R; Koch J; Brehm C; Soerensen J; Gardlowski T; Brinkmann A; Bader P; Passweg J; Klingebiel T; Schwabe D; Koehl U
Eur J Immunol; 2010 Nov; 40(11):3255-67. PubMed ID: 21061445
[TBL] [Abstract][Full Text] [Related]
8. Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector.
Uçar K; Seeger RC; Challita PM; Watanabe CT; Yen TL; Morgan JP; Amado R; Chou E; McCallister T; Barber JR
Cancer Gene Ther; 1995 Sep; 2(3):171-81. PubMed ID: 8528960
[TBL] [Abstract][Full Text] [Related]
9. Enhanced resection and improved survival in murine neuroblastoma (C1300-NB) after preoperative immunotherapy.
Fowler CL; Brooks SP; Squire R; Rich GA; Rossman JE; Finegold MJ; Allen JE; Cooney DR
J Pediatr Surg; 1991 Apr; 26(4):381-7; discussion 387-8. PubMed ID: 2056397
[TBL] [Abstract][Full Text] [Related]
10. Differentiation induced by physiological and pharmacological stimuli leads to increased antigenicity of human neuroblastoma cells.
Carlson LM; Påhlman S; De Geer A; Kogner P; Levitskaya J
Cell Res; 2008 Mar; 18(3):398-411. PubMed ID: 18268541
[TBL] [Abstract][Full Text] [Related]
11. The relationship of class I MHC antigen expression to stage IV-S disease and survival in neuroblastoma.
Squire R; Fowler CL; Brooks SP; Rich GA; Cooney DR
J Pediatr Surg; 1990 Apr; 25(4):381-6. PubMed ID: 2329454
[TBL] [Abstract][Full Text] [Related]
12. Beta 2-microglobulin expression in human embryonal neuroblastoma reflects its developmental regulation.
Cooper MJ; Hutchins GM; Mennie RJ; Israel MA
Cancer Res; 1990 Jun; 50(12):3694-700. PubMed ID: 2187600
[TBL] [Abstract][Full Text] [Related]
13. A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.
Kroesen M; Nierkens S; Ansems M; Wassink M; Orentas RJ; Boon L; den Brok MH; Hoogerbrugge PM; Adema GJ
Int J Cancer; 2014 Mar; 134(6):1335-45. PubMed ID: 24038106
[TBL] [Abstract][Full Text] [Related]
14. Expression of class I histocompatibility antigens in neuroectodermal tumors is independent of the expression of a transfected neuroblastoma myc gene.
Feltner DE; Cooper M; Weber J; Israel MA; Thiele CJ
J Immunol; 1989 Dec; 143(12):4292-9. PubMed ID: 2687378
[TBL] [Abstract][Full Text] [Related]
15. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy.
Garrido F; Cabrera T; Aptsiauri N
Int J Cancer; 2010 Jul; 127(2):249-56. PubMed ID: 20178101
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of MHC class I-deficient tumors.
Reiniš M
Future Oncol; 2010 Oct; 6(10):1577-89. PubMed ID: 21062157
[TBL] [Abstract][Full Text] [Related]
17. Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression.
Blanchet O; Bourge JF; Zinszner H; Israel A; Kourilsky P; Dausset J; Degos L; Paul P
Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3488-92. PubMed ID: 1565643
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma.
Spel L; Boelens JJ; van der Steen DM; Blokland NJ; van Noesel MM; Molenaar JJ; Heemskerk MH; Boes M; Nierkens S
Oncotarget; 2015 Nov; 6(34):35770-81. PubMed ID: 26452036
[TBL] [Abstract][Full Text] [Related]
19. [A novel experimental approach to immunotherapy against malignant brain tumor with the mouse IFN-gamma gene transfer].
Nishihara K
Nihon Geka Hokan; 1989 Jan; 58(1):18-42. PubMed ID: 2508589
[TBL] [Abstract][Full Text] [Related]
20. Regulation of MHC class I and beta 2-microglobulin gene expression in human neuronal cells. Factor binding to conserved cis-acting regulatory sequences correlates with expression of the genes.
Drew PD; Lonergan M; Goldstein ME; Lampson LA; Ozato K; McFarlin DE
J Immunol; 1993 Apr; 150(8 Pt 1):3300-10. PubMed ID: 8468472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
